Literature DB >> 22697083

Skewed T-cell receptor variable β repertoire and massive T-cell activation in idiopathic orofacial granulomatosis.

A Giovannetti, F Mazzetta, A Cavani, D Pennino, E Caprini, E Ortona, G Donato, E Rosato, F Salsano, M Pierdominici.   

Abstract

Orofacial granulomatosis (OFG) is a clinicopathologic entity describing oral lesions with noncaseating granulomas including a spectrum of diseases such as the Melkersson-Rosenthal syndrome. The involvement of abnormal T-cell responses has been suggested in the pathogenesis of OFG although few and contrasting data are currently available on this issue. In a patient with OFG, we observed virtually complete CD4 and CD8 T-cell receptor (TCR) β-chain variable region (BV) repertoires at the lesion level and in circulation. However, oligoclonal profiles were found in CD4 and, to a greater extent, in CD8 subsets. These findings were seen in association with a massive peripheral T-cell activation, decreased naive T cells, reduced thymic output, altered cytokine production, and increased apoptosis. Our data, pointing to a random influx of T cells at the site of inflammation, argue against the hypothesis of a main allergen acting at the level of oral mucosa. The profound dysregulation of the peripheral T-cell compartment suggests that OFG should be regarded as a systemic disorder with localized manifestations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22697083     DOI: 10.1177/039463201202500221

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  3 in total

1.  A 49-year-old man with unilateral, nontender left eyelid swelling.

Authors:  Brandon J Wong; Bryan K Hong; Daman Samrao; Gene H Kim; Narsing A Rao
Journal:  Digit J Ophthalmol       Date:  2014-01-18

2.  Idiopathic orofacial granulomatosis - a diagnostic and treatment challenge.

Authors:  R Vishwanath Rangdhol; N Madhulika; A Dany; S Jeelani; G S Asokan
Journal:  J Clin Diagn Res       Date:  2014-11-20

3.  An extraordinary form of the Melkersson-Rosenthal syndrome successfully treated with the tumour necrosis factor-α blocker adalimumab.

Authors:  Juergen Stein; Alexander Paulke; Beate Schacher; Matthias Noehte
Journal:  BMJ Case Rep       Date:  2014-05-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.